Cellular therapy · BLA
Abecma (idecabtagene vicleucel) NDC 59572-515
Idecabtagene vicleucel 300000000 1/1 · Suspension · Intravenous · Celgene Corporation
NDC codes
FDA NDC Directory| Package NDC | 11-digit (billing) | Package | Copy |
|---|---|---|---|
| 59572-515-01 | 59572051501 | 1 SUSPENSION in 1 BAG (59572-515-01)Marketed from Mar 26, 2021 | |
| 59572-515-02 | 59572051502 | 1 SUSPENSION in 1 BAG (59572-515-02)Marketed from Mar 26, 2021 | |
| 59572-515-03 | 59572051503 | 1 SUSPENSION in 1 BAG (59572-515-03)Marketed from Mar 26, 2021 |
How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules
Product information
- Brand name (proprietary)
- Abecma
- Generic name (nonproprietary)
- idecabtagene vicleucel
- Active ingredients
- Idecabtagene vicleucel — 300000000 1/1
- Dosage form
- Suspension
- Route
- Intravenous
- Labeler
- Celgene Corporation
- Product type
- Cellular therapy
- Marketing category
- BLA — Biologics License ApplicationApplication BLA 125736
- Marketing start
- Listing expires
- Identifiers
- Product ID 59572-515_4adbd9af-42bb-4e51-86fc-b06ccd213b43SPL ID 4adbd9af-42bb-4e51-86fc-b06ccd213b43SPL set ID b90c1fe7-f5cc-464e-958a-af36e9c26d7cRxCUI 2536434, 2536439, 2536443, 2536445, 2536449, 2536451UNII 8PX1X7UG4D
Billing references
What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.
- HCPCS codeNo match
No drug-specific HCPCS code in Med-Code's directory for this product. The directory is curated and not complete — check the current CMS HCPCS file before billing.
- Administration
Drug administration (CPT 96360–96549)
When a clinician administers the drug, the administration is reported separately. Codes in this range cover hydration, therapeutic injections and infusions, and chemotherapy or other complex drug administration. The right code depends on route, duration and drug type, and self-administered drugs are not billed this way.
- NDC on a medical claim
N459572051501followed by a unit qualifier and the quantityPackage 59572-0515-01. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier
Product label
Current FDA label (SPL), effective . This label includes a boxed warning.
Indications (excerpt from the label)
ABECMA is indicated for the treatment of adult patients with relapsed or refractory multiple myeloma after two or more prior lines of therapy including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 monoclonal antibody. ABECMA is a B-cell maturation antigen (BCMA)-directed genetically modified autologous T cell immunotherapy indicated for the treatment of adult patients with relapsed or refractory multiple myeloma after two or more prior lines of therapy including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 monoclonal antibody. ( 1 )
Excerpt only. Read the full label for complete information.